D.C. Circuit Court Stays Approval Of Pravachol ANDAs
This article was originally published in The Pink Sheet Daily
Executive Summary
The D.C. Circuit Court of Appeals enjoined FDA from granting final approval to any ANDA for generic versions of Bristol-Myers Squibb's cholesterol therapy Pravachol (pravastatin) April 20